ArticleScientific reports2025
A Stable and Dependable Visual Technique for On-Site Nipah Virus Nucleic Acids Detection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recent Advances in Lateral Flow Immunoassay for Rapid Diagnosis of Viral Diseases.Transboundary and emerging diseases · 2026Review
- Construction of a portable multiplex detection system for four bee viral paralysis diseases based on RT-PCR-microfluidic chip integrated technology.BMC veterinary research · 2025Article
- Laboratory Diagnosis of Hendra and Nipah: Two Emerging Zoonotic Diseases with One Health Significance.Viruses · 2025Review
- A Highly Specific Antibody-Based Assay forViruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The Nipah Virus (NiV) is a zoonotic pathogen with the mortality rate of up to 75%, recurring in Asia over the past two decades. Due to increasing the risk of human transmission mediated by various intermediate hosts such as pigs and bats, it is necessary to produce an accurate and reliable point-of-care molecular detection method for NiV field diagnosis. In this study, we designed two pairs of primers targeting the conserved G and P genes and developed a point-of-care nucleic acid detection (POC-NAD) system by integrating one-step RT-PCR, lateral flow immunoassay, and microfluidic technologies. The POC-NAD system shows high specificity and sensitivity, with a Limit of Detection (LoD) of 199.1 copies/rxn. The primers aiming to the conserved sequences enables simultaneous detection of both NiV-M and NiV-B strains. Continuous evaluation of 21 simulated clinical samples demonstrated 100% concordance with RT-PCR results. Lateral flow-based visualization improves the display time and legibility of RT-PCR results. Additionally, microfluidic chips or chambers offer disposable reagent containers and consistent PCR amplification results across various field conditions. Therefore, the diagnostic tool is suitable for real-time nucleic acid testing and NiV surveillance in resource-limited field environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.